Profiles Analysis of Genome Wide Association Study (GWAS) in Acne Vulgaris in Indonesia.

ConditionAcne Vulgaris
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age17-60
SponsorDr.dr.Irma Bernadette, SpKK (K)

About this trial

This study is a series of descriptive-analytic studies on genomic variants in the facial skin of patients with AV at the Dermatology and Venereology Polyclinic by determining the genetic profile by GWAS examination in AVB and analysing the genetic profile in AVB against differences in geographical location. The research design used was a cross-sectional design.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Males or females with AVB aged 17-21 years

Both parents of complete subjects with or without a history of acne vulgaris aged up to 60 years

Patients and parents are willing to participate in the study and sign informed consent.

Disqualifiers

Patients who have other inflammatory or infectious diseases especially on the face

Have genetic diseases or disorders

Diagnosed with primary or secondary immunodeficiency diseases

Using oral or systemic antibiotic, anti-inflammatory, retinoid or hormone therapy in the past month.

Trial design

Design model

Parallel

Treatments tested in this trial

  • GWAS

    Genetic

    In GWAS studies, data are collected to determine common variants in a number of individuals, either with or without a common trait (for example,. disease) across the genome, using genome wide SNP arrays.

Treatment groups

24 Participants
are divided into 2 treatment groups
Group A: Lifestyle counselingExperimental treatment 1 intervention
Group B: clinical examinationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Severity of acne vulgaris

Physical examination: identify the number of blackheads, papules, pustules and cysts. Degree of severity:(1)Mild =Comedo\<20, or inflammatory lesion\<15, or total lesion\<30(2)Moderate = Comedo 20-100, or inflammatory lesion15-50, or total lesion 30-125(3)Severe =cyst\>5, or Comedo\>100, or inflammatory lesion\>50, or total lesion\>125.

Time frame
1 year
2

Population structure

Gene testing of blood sample Genetic Inflation Factor (GIF) \>1.1 or \<1.1 Principal Component Analysis (PCA)

Time frame
3 months
3

Genomic Profile

Blood sample examination, processed using GWAS Mutations (SNPs)(1)Present(2)Absent

Time frame
3 months
4

Linkage disequilibirium (LD)

Gene testing of blood samples Coefficient 0-1

Time frame
3 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dr.dr.Irma Bernadette, SpKK (K)

Lead sponsor

Indonesia University

Sponsor institution

Indonesia Medical Education and Research Institute

Collaborator